Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co Days Payable Chart
Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Neptunus Interlong Bio-Technique Co Days Payable vs Drug Manufacturers Industry
Shenzhen Neptunus Interlong Bio-Technique Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) has a Days Payable of 40.28 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. This is 46% below median its historical median of 74.47. Over the past decade, Shenzhen Neptunus Interlong Bio-Technique Co's Days Payable has ranged from 45.78 to 254.17. According to the industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #540 out of 928 companies in the Drug Manufacturers industry, placing it in the top 58.2%.
Is Shenzhen Neptunus Interlong Bio-Technique Co's Days Payable too high?
Shenzhen Neptunus Interlong Bio-Technique Co's current Days Payable of 40.28 is 46% below median its 10-year median of 74.47. Over the past 10 years, this metric has ranged from a low of 45.78 to a high of 254.17. The Drug Manufacturers industry median Days Payable is 88.39. Shenzhen Neptunus Interlong Bio-Technique Co's value of 40.28 is 54.4% below this industry median. Based on the distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #540 out of 928 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shenzhen Neptunus Interlong Bio-Technique Co has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Neptunus Interlong Bio-Technique Co's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #540 out of 928 companies for Days Payable. This places Shenzhen Neptunus Interlong Bio-Technique Co in the lower half of its industry. The industry median Days Payable is 88.39. Shenzhen Neptunus Interlong Bio-Technique Co's value of 40.28 is 54.4% below this benchmark. Historically, Shenzhen Neptunus Interlong Bio-Technique Co's own Days Payable has ranged from 45.78 to 254.17 over the past decade. While the company's 10-year median is 74.47 vs. the industry median of 88.39, Shenzhen Neptunus Interlong Bio-Technique Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.39, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Neptunus Interlong Bio-Technique Co's current Days Payable of 40.28 is 54.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Neptunus Interlong Bio-Technique Co's current Days Payable is 40.28, which is 46% below median its own 10-year median of 74.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Neptunus Interlong Bio-Technique Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.11 — trading 25% below its estimated fair value. The current Days Payable is 40.28, which is 46% below median its 10-year median of 74.47 and 54.4% below the Drug Manufacturers industry median of 88.39. Shenzhen Neptunus Interlong Bio-Technique Co's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329), the current Days Payable is 40.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co stock appears to be undervalued.
The current stock price of HK$0.11 is trading 25% below its estimated GF Value™ of HK$0.14.
GuruFocus considers Shenzhen Neptunus Interlong Bio-Technique Co to be Modestly Undervalued.
Key valuation signals for HKSE:08329:
Days Payable: 40.28 (46% below median its 10-year median of 74.47)
GF Value™: HK$0.14 vs. price of HK$0.11 (25% below fair value)
Industry Position: 54.4% below the Drug Manufacturers median (#540 of 928)
No single metric tells the full story. See the HKSE:08329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.
48GF Score
Get the complete analysis for HKSE:08329
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08329 has been successfully added to your 
